Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
Early Phase 1
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00945607Early Phase 1Unknown

Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer

Role: collaborator

NCT00516100Phase 1Unknown

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Role: lead

NCT00518583Phase 2Unknown

Phase II Study in Patients With Operable Breast Cancer

Role: lead

All 3 trials loaded